메뉴 건너뛰기




Volumn 68, Issue 2, 2004, Pages 172-173

Successful Treatment of Primary Cardiac Lymphoma with Monoclonal CD20 Antibody (Rituximab)

Author keywords

Antibody; B cells; Cardiac tumor; Lymphoma

Indexed keywords

CD20 ANTIBODY; CD20 ANTIGEN; RITUXIMAB;

EID: 10744224381     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.172     Document Type: Article
Times cited : (28)

References (6)
  • 1
    • 0034051844 scopus 로고    scopus 로고
    • A case of primary cardiac B cell lymphoma associated with ventricular tachycardia, successfully treated with systemic chemotherapy and radiotherapy: A long-term survival case
    • Miyashita T, Miyazawa I, Kawaguchi T, Kasai T, Yamaura T, Ito T, et al. A case of primary cardiac B cell lymphoma associated with ventricular tachycardia, successfully treated with systemic chemotherapy and radiotherapy: A long-term survival case. Jpn Circ J 2000; 64: 135-138.
    • (2000) Jpn Circ J , vol.64 , pp. 135-138
    • Miyashita, T.1    Miyazawa, I.2    Kawaguchi, T.3    Kasai, T.4    Yamaura, T.5    Ito, T.6
  • 2
    • 0030822017 scopus 로고    scopus 로고
    • Primary cardiac lymphoma in immunocompetent patients: Diagnostic and therapeutic management
    • Ceresoli GL, Ferreri AJM, Bucci E, Ripa C, Ponzoni M, Villa E. Primary cardiac lymphoma in immunocompetent patients: Diagnostic and therapeutic management. Cancer 1997; 80: 1497-1506.
    • (1997) Cancer , vol.80 , pp. 1497-1506
    • Ceresoli, G.L.1    Ferreri, A.J.M.2    Bucci, E.3    Ripa, C.4    Ponzoni, M.5    Villa, E.6
  • 3
    • 0027371062 scopus 로고
    • Tumors of the heart: A 20-year experience with a review of 12,485 consecutive autopsies
    • Lam KY, Dickens P, Chan ACL. Tumors of the heart: A 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med 1993; 117: 1027-1031.
    • (1993) Arch Pathol Lab Med , vol.117 , pp. 1027-1031
    • Lam, K.Y.1    Dickens, P.2    Chan, A.C.L.3
  • 5
    • 0345337254 scopus 로고    scopus 로고
    • Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
    • McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
    • (1998) J Clin Oncol , vol.16 , pp. 2825-2833
    • McLaughlin, P.1    Grillo-Lopez, A.J.2    Link, B.K.3    Levy, R.4    Czuczman, M.S.5    Williams, M.E.6
  • 6
    • 0032530342 scopus 로고    scopus 로고
    • Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
    • Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 1927-1932.
    • (1998) Blood , vol.92 , pp. 1927-1932
    • Coiffier, B.1    Haioun, C.2    Ketterer, N.3    Engert, A.4    Tilly, H.5    Ma, D.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.